Giants vs. Jets Face-Off: Treatment Options and the Present Status of Non-Small Cell Lung Tumors in Patients who Test Positive for ALK

home / face-off / giants-vs-jets-face-off-treatment-options-and-the-present-status-of-non-small-cell-lung-tumors

A panel of experts discussing treatment for ALK positive for non-small cell malignancies.

Introduction of the Debate Between Jets v. Giants

EP. 1: Introduction of the Debate Between Jets v. Giants

Deborah Doroshow, MD;Neel Chudgar, MD;Vamsidhar Velcheti, MD;Daniel R. Gomez, MD;Jamie E Chaft, MD;Fred R. Hirsch, MD, PhD;Mark G. Kris, MD
December 7th 2023

An outline of the debate, the speakers, and the basic guidelines to support the program.

Brigatinib Versus Crizotinib in ALK inhibitor-Naïve Advanced ALK-Positive NSCLC: Results of Phase 3 ALTA-1L Trial

EP. 2: Brigatinib Versus Crizotinib in ALK inhibitor-Naïve Advanced ALK-Positive NSCLC: Results of Phase 3 ALTA-1L Trial

Deborah Doroshow, MD;Neel Chudgar, MD;Vamsidhar Velcheti, MD;Daniel R. Gomez, MD;Jamie E Chaft, MD;Fred R. Hirsch, MD, PhD;Mark G. Kris, MD
December 7th 2023

Results of phase 3 ALTA-1L study comparing crizotinib with Brigatinib in advanced ALK-positive non-small cell lung cancer

Adjuvant Osimertinib for Resected EGFR Mutated Stage IB-IIIA Non-Small Cell Lung Cancer

EP. 3: Adjuvant Osimertinib for Resected EGFR Mutated Stage IB-IIIA Non-Small Cell Lung Cancer

Deborah Doroshow, MD;Neel Chudgar, MD;Vamsidhar Velcheti, MD;Daniel R. Gomez, MD;Jamie E Chaft, MD;Fred R. Hirsch, MD, PhD;Mark G. Kris, MD
December 14th 2023

EGFR-mutated stage IB-IIIA non-small cell lung carcinoma that has been removed and treated with adjuvant osimertinib.

Will Combination Therapies Replace Osimertinib Monotherapy as Standard-of-Care in Frontline EGFR-Mutant Advanced NSCLC?

EP. 4: Will Combination Therapies Replace Osimertinib Monotherapy as Standard-of-Care in Frontline EGFR-Mutant Advanced NSCLC?

Deborah Doroshow, MD;Neel Chudgar, MD;Vamsidhar Velcheti, MD;Daniel R. Gomez, MD;Jamie E Chaft, MD;Fred R. Hirsch, MD, PhD;Mark G. Kris, MD
December 14th 2023

Osimertinib monotherapy as the standard of treatment for frontline EGFR mutant advanced NSCLC will be replaced by combination therapies.

Treatment for Borderline Resectable Patients With NSCLC

EP. 5: Treatment for Borderline Resectable Patients With NSCLC

Deborah Doroshow, MD;Neel Chudgar, MD;Vamsidhar Velcheti, MD;Daniel R. Gomez, MD;Jamie E Chaft, MD;Fred R. Hirsch, MD, PhD;Mark G. Kris, MD
December 21st 2023

Discussion on the treatment for borderline resectable patients with NSCLC.

Optimal Approach for PD-L1 >50%

EP. 6: Optimal Approach for PD-L1 >50%

Deborah Doroshow, MD;Neel Chudgar, MD;Vamsidhar Velcheti, MD;Daniel R. Gomez, MD;Jamie E Chaft, MD;Fred R. Hirsch, MD, PhD;Mark G. Kris, MD
December 21st 2023

Discussion regarding immunotherapy alone or in combination with chemotherapy for patients with NSCLC that are PD-L1 >50%.

Cancer Network Faceoff: Conclusion of the Event and Presentation of Awards

EP. 7: Cancer Network Faceoff: Conclusion of the Event and Presentation of Awards

Deborah Doroshow, MD;Neel Chudgar, MD;Vamsidhar Velcheti, MD;Daniel R. Gomez, MD;Jamie E Chaft, MD;Fred R. Hirsch, MD, PhD;Mark G. Kris, MD
December 28th 2023

Conclusion of the discussion and award presentation.

Clinicians Face Off Regarding New Trials in NSCLC Space

EP. 8: Clinicians Face Off Regarding New Trials in NSCLC Space

ONCOLOGY Staff
February 11th 2024

The CROWN and ADURA trials were discussed and defended as part of a non–small cell lung cancer Face Off.